Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANDROID 5 vs ISMOTIC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.
Isosmotic solution of mannitol; increases plasma osmolality, drawing water from tissues into the vasculature and reducing intracranial/intraocular pressure via osmotic diuresis.
Testosterone replacement therapy for male hypogonadism,Off-label: delayed puberty in males
Reduction of elevated intracranial pressure,Reduction of elevated intraocular pressure,Promotion of diuresis in acute renal failure (off-label)
2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.
1-2 g orally every 6-8 hours, maximum 8 g/day; or 1-2 g intravenously over 5-10 minutes every 6-8 hours, maximum 8 g/day.
Terminal elimination half-life is 3.5–5.5 hours; clinical effects may persist for several days due to active metabolites.
4.5-6.0 hours in adults with normal renal function; prolonged in renal impairment (up to 24-48 hours in anuria)
Hepatic via CYP3A4 and CYP2B6; undergoes first-pass metabolism.
Not significantly metabolized; primarily excreted unchanged by the kidneys.
Primarily renal: ~90% as glucuronide and sulfate conjugates, 6% as unchanged drug; ~5% fecal via bile.
Renal: 90-95% unchanged; biliary/fecal: <5%
98% bound to sex hormone-binding globulin (SHBG) and albumin.
<10% (negligible), primarily albumin
Vd approximately 1.0 L/kg; indicates extensive tissue distribution, especially to reproductive organs and bone marrow.
0.5-0.7 L/kg; limited to extracellular fluid compartment
Oral: 15–25% due to first-pass metabolism; buccal or transdermal: higher, but not commercially available for this formulation.
Oral: 60-70% (first-pass metabolism); Intravenous: 100%
No specific dose adjustment required based on GFR; caution in severe impairment (Cr Cl <30 m L/min) due to potential fluid retention.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: administer every 12 hours; GFR <10 m L/min: administer every 24 hours.
Contraindicated in Child-Pugh class B and C cirrhosis due to hepatotoxicity risk; in class A, use with caution and monitor liver function.
No adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Avoid in severe hepatic impairment (Child-Pugh C) due to risk of hepatic encephalopathy.
Not recommended for use in children as it may cause premature epiphyseal closure and virilization; limited data.
25-50 mg/kg orally every 6-8 hours, maximum 2 g/dose; or 25-50 mg/kg intravenously over 5-10 minutes every 6-8 hours, maximum 2 g/dose.
Increased risk of prostatic hyperplasia and carcinoma; use lowest effective dose with regular prostate monitoring.
Initiate at low end of dosing range (1 g every 8 hours) due to age-related renal function decline; adjust based on creatinine clearance.
Warning: Prolonged use may cause virilization in women, premature epiphyseal closure, and increased risk of prostatic hypertrophy/carcinoma.
None.
Monitor liver function, lipid profile, and prostate-specific antigen; risk of edema in patients with cardiac disease; avoid use in patients with sleep apnea.
Monitor renal function and serum electrolytes,Avoid in patients with anuria or severe renal impairment,Risk of pulmonary edema, heart failure, and electrolyte disturbances
Known or suspected prostate cancer; breast cancer in males; hypersensitivity to androgens; pregnancy and lactation.
Anuria,Severe renal failure,Congestive heart failure,Active intracranial bleeding (except during craniotomy),Hypovolemia
Avoid grapefruit and grapefruit juice as they may increase drug levels. Limit salt intake to reduce fluid retention. Alcohol may increase risk of liver toxicity.
Avoid high-tyramine foods (aged cheeses, cured meats, soy products) as hydralazine may increase tyramine sensitivity? No significant specific food interactions for isosorbide dinitrate/hydralazine. However, limit high-salt foods to manage heart failure. Avoid alcohol due to additive hypotensive effects.
Pregnancy Category X. ANDROID 5 (oxandrolone) is contraindicated in pregnancy due to teratogenic effects including masculinization of female fetus, clitoral enlargement, and labial fusion. Risk is highest during first trimester but applies throughout gestation.
No adequate and well-controlled studies in pregnant women. In animal studies, administration of isosorbide dinitrate (active ingredient of Ismotic) during organogenesis produced fetal toxicity at doses 35 times the maximum human dose. First trimester: unknown risk, avoid unless clearly needed. Second and third trimesters: risk of maternal hypotension and reduced placental perfusion; use only if potential benefit justifies risk. Should be used with caution near term due to risk of neonatal hypotension.
Excretion into human milk is unknown. Due to potential for androgenic effects in nursing infants, breastfeeding is not recommended. No M/P ratio available.
Isosorbide dinitrate is excreted in human breast milk; clinical significance unknown. M/P ratio not reported. Caution is advised; consider temporary discontinuation of breastfeeding during therapy.
Not applicable; contraindicated in pregnancy. No dose adjustment recommendations exist for pregnant patients.
Pregnancy may alter pharmacokinetics: increased plasma volume and renal clearance may reduce drug concentrations. However, no specific dose adjustments are recommended; titrate based on clinical response and tolerability. Start at lowest effective dose, increase cautiously. Avoid rapid dose escalation. Consider lower doses in third trimester due to increased sensitivity to vasodilation.
Android 5 (methyltestosterone) is an androgenic anabolic steroid used for hypogonadism and delayed puberty. Monitor liver function due to hepatotoxicity. Use with caution in elderly due to increased risk of prostatic hypertrophy and carcinoma. Can cause fluid retention in patients with cardiac, renal, or hepatic disease. Avoid in patients with breast cancer or known or suspected prostate cancer.
ISOMOTIC (isosorbide dinitrate/hydralazine) is a fixed-dose combination for heart failure in self-identified Black patients. Monitor for hypotension, headache, and dizziness. Avoid use with PDE-5 inhibitors (e.g., sildenafil) due to risk of severe hypotension. Titrate gradually to target dose to minimize adverse effects. May cause drug-induced lupus-like syndrome or peripheral neuropathy with hydralazine; consider slow acetylator phenotype risk.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Report any signs of liver problems: yellowing of skin or eyes, dark urine, severe stomach pain.,Women should report any signs of virilization: hoarseness, acne, menstrual changes, growth of facial hair.,Men should report any breast enlargement, changes in urination, or priapism.,Avoid driving or operating machinery if you experience dizziness or drowsiness.,Do not use if you are pregnant or planning to become pregnant.
Take this medication exactly as prescribed to control your heart failure symptoms.,Do not take erectile dysfunction medicines (like sildenafil, tadalafil) while on this drug, as it can cause a dangerous drop in blood pressure.,You may experience headaches, dizziness, or lightheadedness when starting; these often improve over time. If severe, contact your doctor.,Avoid alcohol, which can worsen dizziness and low blood pressure.,Report any unexplained joint pain, fever, rash, or numbness/tingling in your hands or feet to your doctor immediately.,Swallow tablets whole; do not crush or chew.,Do not stop suddenly without consulting your doctor; abrupt discontinuation can worsen heart failure.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANDROID 5 vs ISMOTIC, answered by our medical review team.
ANDROID 5 is a Androgen that works by Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.. ISMOTIC is a Osmotic Diuretic that works by Isosmotic solution of mannitol; increases plasma osmolality, drawing water from tissues into the vasculature and reducing intracranial/intraocular pressure via osmotic diuresis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANDROID 5 and ISMOTIC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANDROID 5 is: 2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.. The standard adult dose of ISMOTIC is: 1-2 g orally every 6-8 hours, maximum 8 g/day; or 1-2 g intravenously over 5-10 minutes every 6-8 hours, maximum 8 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANDROID 5 and ISMOTIC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANDROID 5 is classified as Category C. Pregnancy Category X. ANDROID 5 (oxandrolone) is contraindicated in pregnancy due to teratogenic effects including masculinization of female fetus, clitoral enlargement, and labial. ISMOTIC is classified as Category C. No adequate and well-controlled studies in pregnant women. In animal studies, administration of isosorbide dinitrate (active ingredient of Ismotic) during organogenesis produced fe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.